Sei sulla pagina 1di 13

CONDITION TRIAL IDENTIFIER

NCT01933529

NCT01862029

Prediabetes NCT01521312

NCT01773707

2009-011003-23/FR
NCT01030861

NCT02005848
Type 1 DM NCT02000817

NCT02044848
NCT01947569

NCT01845064

NCT01889667
Type 2 DM
NCT01918865

NCT01970046

NCT02020616

NCT01329016

NCT01018602
Gestational
Diabetes
NCT01662921

NCT01731431

NCT01856907
NCT01822925

Diabetes-related “- NCT01928381
opathies” (need
something about NCT01863810
retinopathy)
NCT01889277
NCT01843387
NCT01994291

consider adding NCT02050828

NCT01858597
NCT00572689

Hypoglycemia
http://clinicaltrials.gov/ct2/show/NCT01841359?term=hypoglycemia&recr=Open&cntry1=NA%3AUS&rank=5
NCT01994746 Hypoglycemia
NCT02081014 Hypoglycemia

hyperglycemia +
NCT01875107 pregnant
stress hyperglycemia
NCT01969149
Study name

ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals

ACute and Chronic Effects of Saxagliptin (ACCES)


CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for
Type 1

A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35
days in patients presenting with impaired glucose tolerance and abdominal obesity. A double blind,
parallel group, placebo-controlled and randomized study
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

Phase II-III Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus


Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy
A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes
Patients
Safety, Pharmacokinetics and Pharmacodynamics of Multiple Oral Bedtime Doses of ORMD-0801 in Adult
Patients With Type 2 Diabetes

Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)

PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)

Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of
Gestational Diabetes (INDAO)
Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent
GDM
Safety Study of DA-9801 to Treat Diabetic Neuropathy
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With
PDN and Good Pain Reporting Ability

Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain

Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy
Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor
Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
Safety and Efficacy of AKB-9778 as Monotherapy or Adjunctive to Ranibizumab Compared to
Ranibizumab Monotherapy in Subjects With Diabetic Macular Edema

Fibroblast Growth Factors 19 and 21 in Gestational Diabetes Mellitus


Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
Annie comments

Interesting approach (pro) - Sweden only (con)

Good - NIH study, unique approach (new MOA)


DPP-IV inhibitor. Several in this class marketed for T2DM but none for
prediabetes (pro) - France only

Very good study but more appropriate for Type 1!!

PPAR agonist. Rosiglitazone was previously evaluated in CT3 for prediabetes


but study was discontinued due to recruitment difficulties - France only
good - NIDDK study - biologic therapy

interesting approach (alpha1-antitrypsin) - Israel only, company-sponsored


interesting (biologic therapy) - Belgium only, company-sponsored

interesting (biologic therapy) - conducted in USA, company-sponsored


Very interesting, cell therapy, conducted in USA

Interesting, recombinant protein, first study in humans - Netherlands only

oral insulin, company-sponsored, conducted in USA


antisense therapy (very novel - pro) - conducted in Canada and South
Africa, company-sponsored

another DPP-IV inhibitor (not novel), China only - I would not include

no chemical structure or MOA information at this time - I would not include


?? - NIH study - not sure why this is novel, abstract says that glyburide and
metformin are already used for GDM

Prevention of type 2 diabetes with vildagliptin in women with gestational


diabetes - clinical trial record not updated since 2011, study was supposed
to end in 2012 - I would not include
Comparison of two insulin analogues (insulin glulisine is currently in phase
II for GDM), conducted in USA
??? - glyburide and insulin are already standard - study conducted in France
- last updated 2012, slated to run through 2015
study to delay progression to type 2 diabetes in women with GDM,
conducted in USA
herbal extract, conducted in USA
Histamine H3 antagonist plus anticonvulsant for painful diabetic
neuropathy - conducted in USA, company-sponsored
KW-21052 appears to be a generic version of pregabalin (=Lyrica).
Noninferiority trial conducted only in Korea. I would not include

conducted in Japan only


Good - cell therapy - conducted in Australia only
Would this qualify as a biomarker study? Drawback: conducted in China
NCT01933529

NCT01862029

NCT01521312

NCT01773707

2009-011003-23
NCT01030861

NCT02005848
NCT02000817

NCT02044848
NCT01947569

NCT01845064

NCT01889667

NCT01918865

NCT01970046

NCT02020616

NCT01329016

NCT01018602

NCT01662921

NCT01731431

NCT01856907
NCT01822925

NCT01928381

NCT01863810

NCT01889277
NCT01843387
http://clinicaltrials.gov/ct2/show/NCT01933529?term=NCT01933529&rank=1

http://clinicaltrials.gov/ct2/show/NCT01933529?term=NCT01933529&rank=1

http://clinicaltrials.gov/ct2/show/NCT01933529?term=NCT01933529&rank=1

http://clinicaltrials.gov/ct2/show/NCT01933529?term=NCT01933529&rank=1

http://clinicaltrials.gov/ct2/show/ ?term= &rank=1


http://clinicaltrials.gov/ct2/show/NCT01933529?term=NCT01933529&rank=1

http://clinicaltrials.gov/ct2/show/NCT01862029?term=NCT01862029&rank=1

http://clinicaltrials.gov/ct2/show/NCT01521312?term=NCT01521312&rank=1

http://clinicaltrials.gov/ct2/show/NCT01773707?term=NCT01773707&rank=1

http://clinicaltrials.gov/ct2/show/2009-011003-23?term=2009-011003-23&rank=1
http://clinicaltrials.gov/ct2/show/NCT01030861?term=NCT01030861&rank=1

http://clinicaltrials.gov/ct2/show/NCT02005848?term=NCT02005848&rank=1
http://clinicaltrials.gov/ct2/show/NCT02000817?term=NCT02000817&rank=1

http://clinicaltrials.gov/ct2/show/NCT02044848?term=NCT02044848&rank=1
http://clinicaltrials.gov/ct2/show/NCT01947569?term=NCT01947569&rank=1

http://clinicaltrials.gov/ct2/show/NCT01845064?term=NCT01845064&rank=1

http://clinicaltrials.gov/ct2/show/NCT01889667?term=NCT01889667&rank=1

http://clinicaltrials.gov/ct2/show/NCT01918865?term=NCT01918865&rank=1

http://clinicaltrials.gov/ct2/show/NCT01970046?term=NCT01970046&rank=1

http://clinicaltrials.gov/ct2/show/NCT02020616?term=NCT02020616&rank=1

http://clinicaltrials.gov/ct2/show/NCT01329016?term=NCT01329016&rank=1

http://clinicaltrials.gov/ct2/show/NCT01018602?term=NCT01018602&rank=1

http://clinicaltrials.gov/ct2/show/NCT01662921?term=NCT01662921&rank=1

http://clinicaltrials.gov/ct2/show/NCT01731431?term=NCT01731431&rank=1

http://clinicaltrials.gov/ct2/show/NCT01856907?term=NCT01856907&rank=1
http://clinicaltrials.gov/ct2/show/NCT01822925?term=NCT01822925&rank=1

http://clinicaltrials.gov/ct2/show/NCT01928381?term=NCT01928381&rank=1

http://clinicaltrials.gov/ct2/show/NCT01863810?term=NCT01863810&rank=1

http://clinicaltrials.gov/ct2/show/NCT01889277?term=NCT01889277&rank=1
http://clinicaltrials.gov/ct2/show/NCT01843387?term=NCT01843387&rank=1
CONDITION TRIAL IDENTIFIER
NCT01659385
NCT01778400
Thyroid nodules NCT00858104
NCT01750593
http://www.ncbi.nlm.nih.gov/pubmed/23780378
NCT01800617
NCT01950260
Hypothyroidism NCT01832753
EudraCT 2010-018663-42
NCT01921452
NCT01611896
NCT01269749
NCT01789541
Hyperthyroidism
NCT01295333
NCT01945229
ISRCTN62749892
NCT01837433
NCT01760421
Thyroiditis
NCT02013479
http://www.ncbi.nlm.nih.gov/pubmed/22168752

http://eanm13.eanm.org/abstracts/session_detail.php?sessionNumber=1508&referer=/progr

Goiter/iodine deficiency http://www.ncbi.nlm.nih.gov/pubmed/23095630


http://www.ncbi.nlm.nih.gov/pubmed/22577172
http://www.ncbi.nlm.nih.gov/pubmed/21715542
http://www.ncbi.nlm.nih.gov/pubmed/21346067
http://www.ncbi.nlm.nih.gov/pubmed/?term=23728841
RESULT LINK

http://www.ncbi.nlm.nih.gov/pubmed/23616630

http://www.ncbi.nlm.nih.gov/pubmed/23782950

http://www.ncbi.nlm.nih.gov/pubmed/21591944
http://www.ncbi.nlm.nih.gov/pubmed/21563916

Title: The influence of single low dose of recombinant


human thyrotropin on I-131 treatment of large
multinodular goitre (Abs OP615).

University of Michigan Health System; but is a case report


Description/Annie comments
Leptin Levels in Papillary Thyroid Cancer (wrong indication?)
radiofrequency ablation vs. ethanol ablation
laser ablation - long term results
radiofrequency ablation as an alternative to surgery
interstitial laser photocoagulation
new formulation of T3? Not sure if this is novel
Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome
L-thyroxine (T4) plus T3 sulfate (T3S). Conducted in Italy
Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Genera
Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism (GRASS)
Radioactive Iodide Therapy for Pediatric Graves' Disease
Is a Low Thyreotropin Level Predictive of Recurrent Arrhythmia After Catheter Ablative Surgery? (TABLAS) - Include?
early prophylactic introduction of low dose of LT4 versus symptomatic therapy
Thumb-ECG Ambulant Screening for Atrial Fibrillation in Hyperthyroid Patients Treated With Radioiodine
Optimum dose finding study of radioiodine
Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis (Conducted only in China)
Effect of Hydroxychloroquine treatment in Hashimoto's Thyroiditis (Conducted in Taiwan only)
Selenium supplementation in autoimmune thyroiditis (Conducted in Denmark only)
CXCL11 and CXCL10 as biomarkers of authoimmune thyroiditis

Even very-low-dose rhTSH increases the values of RAIU in significant way


Hemithyroidectomy versus Dunhill for surgical management of asymmetrical multinodular goiter
Enhanced goiter volume reduction with rhTSH-augmented (131)I therapy
Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination (should be in first section?)
Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter
DICER1 mutation as cause of multinodular goiter in children
lescents with Down syndrome

as Compared to Third Generation TSH Test Kit

TABLAS) - Include?

ld be in first section?)
enign multinodular goiter